ILLUMINA, INC. Q3 FY2026 earnings call

• Strong Clinical Demand: Clinical sequencing demand remains robust, driving revenue, margin, and EPS above guidance. NovoCX instrument placements are at very high levels, with over 80 units placed in Q3, signaling sustained future consumable revenue.
• NovaSeq X Transition Progress: The transition to NovaSeq X is largely complete in research markets (>90% volume) and nearing completion in clinical markets (78% volume). This reduces near-term pricing headwinds and supports margin expansion.
• Innovation & AI Strategy: Illumina is advancing its AI biology strategy through the Billion Cell Atlas, addressing data bottlenecks for drug discovery. Partnerships like GSK highlight growing biopharma interest. The BioInsight platform integrates analysis, AI models, and curated data to lower total workflow costs.
• Operational Efficiency: Operating margins expanded significantly, driven by disciplined cost management and higher revenue. The company demonstrated resilience against external headwinds such as tariffs and component pricing pressures.

Total Q3 revenue was $1.17 billion, up 4.7% year-over-year on a rest-of-world organic basis. Sequencing consumables generated $792 million (up 6% YoY, 5% organic), representing the core growth driver. Sequencing instruments contributed $106 million (down 2% organic), with NovaSeq X placements exceeding 80 units in the quarter. Sequencing services and other revenue reached $158 million (up 8% organic), aided by the Billion Cell Atlas program. Microarrays and other revenue totaled $110 million (up 2% organic), including strong performance from Somalogic.

• Full-Year 2026 Revenue: Raised by $30 million at the midpoint to $4.64–$4.66 billion, reflecting Q3 outperformance and stronger Q4 expectations for consumables.
• Full-Year 2026 Margins & EPS: Operating margins expected at approximately 23.6% (high end of prior guide); Diluted EPS raised to $5.40–$5.45 (up $0.08 at midpoint).
• Q4 2026 Outlook: Revenue expected at $1.22–$1.24 billion; Operating margin approx. 25%; EPS expected at $1.51–$1.56.
• Long-Term Targets: Management reaffirms confidence in achieving long-range financial targets, aiming for high-single-digit growth in 2027 as pricing headwinds lapse.

• Geopolitical Uncertainty in China: Recent regulatory actions and entity list concerns create uncertainty for the Chinese market, though management maintains commitment to serving customers and navigating regulations.
• Research Market Decline: Research and applied sequencing consumables continue to face mid-to-high single-digit declines, contrasting with strong clinical growth.
• Clinical Conversion Pace: While improving, the pace of clinical conversion to NovaSeq X has slowed slightly compared to research, requiring continued monitoring of assay adoption rates.

Q: How should investors view the sustainability of NovaSeq X demand given recent strong placements?

A: CEO Jacob Thaysen stated there is no evidence of pull-forward demand, attributing strength to healthy clinical market conditions and sequencing-intensive new assays. He emphasized that customers view NovaSeq X as the definitive platform for future innovation, ensuring sustained demand beyond initial placement cycles.

Q: What is the framework for 2027 growth given the end of NovaSeq X transition headwinds?

A: Management indicated that 2027 will be driven by consumables growth from the expanded installed base, new multiomics products, and AI-related data services. They expect to return to high-single-digit growth rates, leveraging the completion of the X transition to eliminate previous pricing pressures.

Q: Can Illumina win large-scale AI training projects despite competitors offering cheaper whole-genome sequencing?

A: CEO Thaysen argued that AI value lies in standardized, reproducible functional datasets rather than raw sequencing price. Illumina’s unique position lies in creating large-scale perturbation data via the Billion Cell Atlas, which offers superior utility for model training compared to low-cost, noisy individual datasets.

Q: What is the impact of recent geopolitical developments on the China business?

A: Management acknowledged the uncertainty but reaffirmed their commitment to the Chinese market. They are actively engaging with regulators and customers to ensure continuity. No significant budget flush was anticipated for Q4, but any unexpected positive developments could provide upside.

Q: When will AI and BioInsight contributions become material to the P&L?

A: CFO Ankur Dhingra projected that AI-driven revenue streams, particularly from the Billion Cell Atlas and BioInsight software, would begin contributing meaningfully to growth in 2027, potentially adding 1-2 percentage points to top-line growth as these initiatives scale.